3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Phase 1
1
Status
Recruiting
11
Completed
7
Active not recruiting
6
Withdrawn
2
Terminated
2
Not yet recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
2
Interventions
Cisplatin
22
Carboplatin
15
Radiotherapy
13
Paclitaxel
11
Gemcitabine
10
Rituximab
9
Fluorouracil
9
Drug Therapy
6
Dexamethasone
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
Vinorelbine
4
Pemetrexed
4
Nivolumab
4
Methotrexate
4
Etoposide
4
Docetaxel
4
Bendamustine Hydrochloride
4
spartalizumab
3
pertuzumab
3
pembrolizumab
3
fludarabine
3
Vincristine
3
Trastuzumab
3
Surgical Procedures, Operative
3
Standard of Care
3
Prednisone
3
Oxaliplatin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Withdrawn
×
ribociclib
×
Clear all
NCT06585969
2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3
Withdrawn
NCT03081234
2018-03-15
EarLEE-2
Novartis
Phase 3
Withdrawn